Actively Recruiting
Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-small Cell Lung Cancer
Led by Rutgers, The State University of New Jersey · Updated on 2026-01-30
34
Participants Needed
2
Research Sites
354 weeks
Total Duration
On this page
Sponsors
R
Rutgers, The State University of New Jersey
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This phase II trial studies the effect of adaptive radiation planning in reducing side effects associated with radiation treatment and immunotherapy in patients with stage II-IV non-small cell lung cancer. Prior to radiation, patients undergo simulation, where they are positioned on the treatment table in a manner that can be reproduced each time they receive treatment in order to reach the tumor exactly at the same spot each time. However, a patient's tumor may shrink as they receive radiation, exposing healthy tissue to radiation as well. Adaptive radiation planning involves re-designing a treatment plan at set intervals. The purpose of this study is to see whether establishing set time points through adaptive radiation planning, regardless of whether the doctor notices a significant decrease in tumor size, will reduce some of the side effects associated with radiation treatment and immunotherapy.
CONDITIONS
Official Title
Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-small Cell Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Provide written informed consent and HIPAA authorization
- Have biopsy-proven, locally advanced or oligometastatic stage II-IV non-small cell lung cancer planned for chemoradiation with immunotherapy
- Have ECOG performance status of 0 or 1
- Have adequate organ and marrow function for radiation therapy, confirmed within 14 days before starting treatment
- Women of childbearing potential must have a negative pregnancy test within 30 days before treatment
- Women of childbearing potential must agree to abstain or use effective contraception during the study
- Men sexually active with women of childbearing potential must use contraception with less than 1% failure rate per year
You will not qualify if you...
- Have any condition, therapy, or lab abnormality that could interfere with study participation or results, as judged by the investigator
- Are pregnant, breastfeeding, or planning to conceive or father children during the study
- Have active symptomatic central nervous system metastases or lack prior brain imaging within 28 days before treatment
- Received investigational agents within 28 days before treatment
- Had prior chemotherapy, adjuvant therapy, or radiotherapy for lung cancer other than standard concurrent chemoradiation or up to 2 cycles consolidation therapy
- Have active second cancers
- Have psychiatric illness or social situations limiting study compliance
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States, 08903
Actively Recruiting
2
RWJBarnabas Health - Robert Wood Johnson University Hospital
New Brunswick, New Jersey, United States, 08903
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here